NATURE . COM {}

Matching Content Categories {📚}

• Telecommunications
• Health & Fitness
• Science

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌆 Monumental Traffic: 20M - 50M visitors per month


Based on our best estimate, this website will receive around 42,554,915 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}

Display Ads {🎯}

Direct Advertisers (10)

Reseller Advertisers (38)

How Much Does Nature.com Make? {💰}

Display Ads {🎯}

$536,300 per month
Our analysis indicates Nature.com generates between $357,503 and $983,134 monthly online from display ads.

Keywords {🔍}

cancer, oncogene, res, testa, nature, cell, sci, altomare, access, rev, cheng, article, bellacosa, natl, usa, akt, proc, acad, pathway, content, signaling, human, wang, tsichlis, cookies, lee, genet, clin, nat, liu, privacy, open, biochem, kim, yang, nicosia, oncol, sun, data, review, kinases, activation, kleinszanto, cristofano, science, thomas, trends, pandolfi, feldman, majumder,

Topics {✒️}

nature portfolio permissions reprints cancer research privacy policy nature advertising tumor suppressor genes akt-mtor signalling axis current pharmacologic strategies social media author information authors akt signaling pathway springerlink instant access author correspondence breast cancer res personal data activated tyrosine kinases data protection permissions article altomare tumor suppressors implicated akt pathway human malignancy epigenetic activation article purchase privacy article cite access human cancer deborah inter-related proteins sporadic human cancers explore content subscription content cancer drug targets cancer antonino glavianoaaron european economic area include disorders caused target therapeutically components institutional subscriptions read muise-helmericks rc nih grants ca77429 targeted therapies accepting optional cookies article journals search log pathogenic mechanisms contributing functional activation cancer met rev manage preferences targeting

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Perturbations of the AKT signaling pathway in human cancer
         description:AKT/PKB (protein kinase B) kinases mediate signaling pathways downstream of activated tyrosine kinases and phosphatidylinositol 3-kinase. AKT kinases regulate diverse cellular processes including cell proliferation and survival, cell size and response to nutrient availability, tissue invasion and angiogenesis. Many oncoproteins and tumor suppressors implicated in cell signaling/metabolic regulation converge within the AKT signal transduction pathway in an equilibrium that is altered in many human cancers by activating and inactivating mechanisms, respectively, targeting these inter-related proteins. We review a burgeoning literature implicating aberrant AKT signaling in many sporadic human cancers as well as in several dominantly inherited cancer syndromes known as phakomatoses. The latter include disorders caused by germline mutations of certain tumor suppressor genes, that is, PTEN, TSC2/TSC1, LKB1, NF1, and VHL, encoding proteins that intersect with the AKT pathway. We also review various pathogenic mechanisms contributing to activation of the AKT pathway in human malignancy as well as current pharmacologic strategies to target therapeutically components of this pathway.
         datePublished:2005-11-14T00:00:00Z
         dateModified:2005-11-14T00:00:00Z
         pageStart:7455
         pageEnd:7464
         sameAs:https://doi.org/10.1038/sj.onc.1209085
         keywords:
            AKT/PKB kinases
            tumor suppressor genes
            oncogenes
            human malignancy
            targeted therapy
            Medicine/Public Health
            general
            Internal Medicine
            Cell Biology
            Human Genetics
            Oncology
            Apoptosis
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1209085/MediaObjects/41388_2005_Article_BF1209085_Fig1_HTML.jpg
         isPartOf:
            name:Oncogene
            issn:
               1476-5594
               0950-9232
            volumeNumber:24
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Deborah A Altomare
               affiliation:
                     name:Human Genetics Program, Fox Chase Cancer Center
                     address:
                        name:Human Genetics Program, Fox Chase Cancer Center, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Joseph R Testa
               affiliation:
                     name:Human Genetics Program, Fox Chase Cancer Center
                     address:
                        name:Human Genetics Program, Fox Chase Cancer Center, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Perturbations of the AKT signaling pathway in human cancer
      description:AKT/PKB (protein kinase B) kinases mediate signaling pathways downstream of activated tyrosine kinases and phosphatidylinositol 3-kinase. AKT kinases regulate diverse cellular processes including cell proliferation and survival, cell size and response to nutrient availability, tissue invasion and angiogenesis. Many oncoproteins and tumor suppressors implicated in cell signaling/metabolic regulation converge within the AKT signal transduction pathway in an equilibrium that is altered in many human cancers by activating and inactivating mechanisms, respectively, targeting these inter-related proteins. We review a burgeoning literature implicating aberrant AKT signaling in many sporadic human cancers as well as in several dominantly inherited cancer syndromes known as phakomatoses. The latter include disorders caused by germline mutations of certain tumor suppressor genes, that is, PTEN, TSC2/TSC1, LKB1, NF1, and VHL, encoding proteins that intersect with the AKT pathway. We also review various pathogenic mechanisms contributing to activation of the AKT pathway in human malignancy as well as current pharmacologic strategies to target therapeutically components of this pathway.
      datePublished:2005-11-14T00:00:00Z
      dateModified:2005-11-14T00:00:00Z
      pageStart:7455
      pageEnd:7464
      sameAs:https://doi.org/10.1038/sj.onc.1209085
      keywords:
         AKT/PKB kinases
         tumor suppressor genes
         oncogenes
         human malignancy
         targeted therapy
         Medicine/Public Health
         general
         Internal Medicine
         Cell Biology
         Human Genetics
         Oncology
         Apoptosis
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1209085/MediaObjects/41388_2005_Article_BF1209085_Fig1_HTML.jpg
      isPartOf:
         name:Oncogene
         issn:
            1476-5594
            0950-9232
         volumeNumber:24
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Deborah A Altomare
            affiliation:
                  name:Human Genetics Program, Fox Chase Cancer Center
                  address:
                     name:Human Genetics Program, Fox Chase Cancer Center, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Joseph R Testa
            affiliation:
                  name:Human Genetics Program, Fox Chase Cancer Center
                  address:
                     name:Human Genetics Program, Fox Chase Cancer Center, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Oncogene
      issn:
         1476-5594
         0950-9232
      volumeNumber:24
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Human Genetics Program, Fox Chase Cancer Center
      address:
         name:Human Genetics Program, Fox Chase Cancer Center, Philadelphia, USA
         type:PostalAddress
      name:Human Genetics Program, Fox Chase Cancer Center
      address:
         name:Human Genetics Program, Fox Chase Cancer Center, Philadelphia, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Deborah A Altomare
      affiliation:
            name:Human Genetics Program, Fox Chase Cancer Center
            address:
               name:Human Genetics Program, Fox Chase Cancer Center, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Joseph R Testa
      affiliation:
            name:Human Genetics Program, Fox Chase Cancer Center
            address:
               name:Human Genetics Program, Fox Chase Cancer Center, Philadelphia, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Human Genetics Program, Fox Chase Cancer Center, Philadelphia, USA
      name:Human Genetics Program, Fox Chase Cancer Center, Philadelphia, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(1)

• https://twitter.com/oncogenejournal

External Links {🔗}(17)

• How much does https://link.springer.com/article/10.1038/sj.onc.1209085?utm_source=nature&utm_medium=referral&utm_campaign=buyArticle pull in?
• How much income does https://citation-needed.springer.com/v2/references/10.1038/sj.onc.1209085?format=refman&flavour=references have?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Deborah%20A%20Altomare earn?
• What's the financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Deborah%20A%20Altomare%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Joseph%20R%20Testa rake in every month?
• How much income does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Joseph%20R%20Testa%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have?
• How much revenue does https://s100.copyright.com/AppDispatchServlet?title=Perturbations%20of%20the%20AKT%20signaling%20pathway%20in%20human%20cancer&author=Deborah%20A%20Altomare%20et%20al&contentID=10.1038%2Fsj.onc.1209085©right=Springer%20Nature%20Limited&publication=0950-9232&publicationDate=2005-11-14&publisherName=SpringerNature&orderBeanReset=true produce monthly?
• How much does https://citation-needed.springer.com/v2/references/10.1038/sj.onc.1209085?format=refman&flavour=citation make?
• How much does https://doi.org/10.1038/s41419-024-06476-1 gross monthly?
• How much profit does https://doi.org/10.1007/s00432-024-05780-9 make?
• Revenue of https://doi.org/10.1186/s12894-023-01307-5
• How much revenue does https://doi.org/10.1186/s12943-023-01762-6 produce monthly?
• How much profit does https://doi.org/10.1186/s12943-023-01827-6 generate?
• Income figures for https://www.protocols.io/
• How much revenue does https://www.natureindex.com/ generate?
• How much does http://www.naturechina.com gross monthly?
• What's the financial intake of https://www.natureasia.com/ja-jp?

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Prism.js
• Zoom.js

Emails and Hosting {✉️}

Mail Servers:

• mxa-002c5801.gslb.pphosted.com
• mxb-002c5801.gslb.pphosted.com

Name Servers:

• pdns1.ultradns.net
• pdns2.ultradns.net
• pdns3.ultradns.org
• pdns4.ultradns.org
• pdns5.ultradns.info
• pdns6.ultradns.co.uk

CDN Services {📦}

• Crossref